Acuvi (ACUVI) investor relations material

Executive summary

• Revenue increased to 50.1 MSEK in Q2 2026 from 47.2 MSEK year-over-year, but profitability declined sharply with negative EBITDA and EBIT due to one-time costs and higher expenses.

• Focus on growth potential in semiconductor, med tech, and life science segments, with significant opportunities in Asia and emerging markets.

• Recent investments in Asia have resulted in over 100% growth in the first two quarters of 2026 compared to the previous year.

• Significant organizational changes, including a new CFO and new CEO for TPA Motion, aimed at strengthening sales and operational structure.

• Orders from the US defense sector and entry into Formula 1 highlight strategic wins in high-value segments.

Financial highlights

• Q2 net sales increased by SEK 3 million to SEK 50.1 million year-over-year.

• Operating profit turned negative at SEK -9.3 million for the quarter, with a margin of -18%.

• Gross margin fell from 65% to 51% due to SEK 1.9 million in duties, higher material and tariff costs.

• Cash reserves at quarter-end were SEK 19.8 million, with negative cash flow of SEK 9.5 million for the quarter.

• Net loss for Q2 was -10.4 MSEK (6.7 MSEK profit in Q2 2025); EPS was -0.31 SEK (0.22 SEK).

Outlook and guidance

• Management expects financial results to improve in H2 2026 but not enough to reach the previously communicated EBITDA target.

• Growth anticipated in semiconductor, space, and life science segments, with strong order intake expected in H2.

• Aim to grow PiezoMotor by at least 50% for the full year, despite not expecting to sustain 100% growth.

• Long-term focus on profitable growth, with no specific timeline for sustained profitability.